Neuralstem, Inc.

Neuralstem, Inc. is a groundbreaking biotherapeutics company that has been leading the charge in utilizing stem cell research to combat diseases of the central nervous system since its establishment in 1996. The company's mission, epitomized by their slogan, is to advance stem cell technology to treat central nervous system diseases, offering hope for conditions that were previously deemed incurable. Neuralstem's proprietary human neural stem cell technology has paved the way for significant advancements in the treatment of Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS, and Parkinson’s Disease. This is a monumental achievement in the biotechnology and healthcare industries. One key milestone in their journey includes a noteworthy $7.50MPost-IPO Equity investment received on 31 July 2019. This injection of funding serves as a testament to the promising future of Neuralstem and the confidence that investors have in their pioneering approach to addressing unmet medical needs. With the capability to produce mature, commercial-scale neural stem cells that can be transplanted into humans, Neuralstem is at the forefront of offering tangible solutions for diseases that have previously lacked effective treatments.

Overall, Neuralstem's commitment to innovation and their significant progress in the field of stem cell technology position them as a compelling investment opportunity. The confidence shown by the recent $7.50MPost-IPO Equity investment underscores the potential for substantial growth and impact in the biotechnology and healthcare sectors. As Neuralstem continues to make strides in the development and application of their neural stem cell technology, they are poised to deliver groundbreaking advancements in the treatment of central nervous system diseases, ultimately transforming the landscape of medical care and providing hope for countless individuals affected by these conditions.